Last updated: 2026-10-13 21:15:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Rani Therapeutics Holdings, Inc. (RANI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0,73, with a market capitalisation of $92,22M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,45 to $3,87. This page covers its latest market performance, valuation, price trends and company information.
$92,22M | |
$0,75 | |
$36,27 | |
$0,39 | |
$0,75 | |
891,47K | |
729,04K | |
-- | |
$3,87 | |
$0,45 | |
-- | |
-- |
Rani Therapeutics Holdings, Inc. (RANI) is trading at $0,73 in after-hours trading as of 2026-10-13 20:52:00, down 2,38% ($0,02) from the regular-session close of $0,75.
After-hours trading shows how investors are pricing RANI after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Rani Therapeutics Holdings, Inc. (RANI) moved from $0,81 to $0,73, representing a decline of 10,46% ($0,08).
The stock traded between $0,71 and $0,84 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 473,62 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 8,2%
RANI is currently trading at $0,73, placing it 8,2% of the way from its 52-week low of $0,45 to its 52-week high of $3,87. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 69 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Rani Therapeutics Holdings, Inc. (RANI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.